Is Viridian Therapeutics Inc (VRDN) a Stock to Watch After Gaining 2.34% This Week?

The market has been down on Viridian Therapeutics Inc (VRDN) stock recently. VRDN gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Viridian Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on VRDN!

See Full VRDN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With VRDN Stock Today?

Viridian Therapeutics Inc (VRDN) stock is trading at $19.72 as of 1:11 PM on Monday, Mar 4, a loss of -$0.17, or -0.85% from the previous closing price of $19.89. The stock has traded between $19.48 and $20.50 so far today. Volume today is low. So far 216,233 shares have traded compared to average volume of 906,215 shares.

More About Viridian Therapeutics Inc

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Click Here to get the full Stock Report for Viridian Therapeutics Inc stock.